Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain demyelination and behavioral disturbances

This comprehensive study, published by Sikiric's group in the Journal of Physiology and Pharmacology, simultaneously investigated the effects of BPC-157 in three distinct experimental models in rats: cysteamine-induced colitis, colonic anastomosis healing, and cuprizone-induced brain demyelination. This multi-system approach reflects the research group's philosophy of demonstrating the therapeutic versatility of the peptide.

In the cysteamine colitis model, BPC-157 promoted accelerated healing of colonic mucosal lesions, with significant reduction in macroscopic and histological inflammation scores. In the colon-colon anastomosis model (simulating post-surgical recovery), the peptide improved the mechanical strength of the anastomosis and accelerated tissue remodeling, with greater deposition of organized collagen at the suture site.

Perhaps the most surprising result was in the cuprizone brain demyelination model, which simulates aspects of multiple sclerosis. BPC-157 demonstrated protective effects against myelin loss in the corpus callosum and attenuated the associated behavioral disturbances (anxiety and motor coordination deficits), suggesting a capacity for central nervous system protection.

The importance of this study lies in the demonstration that a single peptide can exert therapeutic effects across such diverse organ systems — gastrointestinal and central nervous — pointing to fundamental mechanisms of action involving conserved tissue repair pathways. The authors proposed that BPC-157 acts as an "organizer" of the healing response, modulating the interaction between the NO system, prostaglandins, and growth factors.